-
Something wrong with this record ?
Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic
Z. Bielcikova, M. Holanek, I. Selingerova, O. Sorejs, I. Kolarova, R. Soumarova, J. Proks, L. Reifova, V. Cmejlova, L. Linkova, M. Zabojnikova, M. Chodacka, L. Janovska, L. Lisnerova, K. Kasparova, D. Pohankova, L. Petruzelka
Language English Country England, Great Britain
Document type Journal Article, Multicenter Study
Grant support
00064165
Ministry of Health of the Czech Republic-conceptual development of research organization
00064165
Ministry of Health of the Czech Republic
NLK
Directory of Open Access Journals
from 2022
Free Medical Journals
from 1996
Freely Accessible Science Journals
from 1996-02-01
PubMed Central
from 2010
Europe PubMed Central
from 2010
Medline Complete (EBSCOhost)
from 2006-09-01
Oxford Journals Open Access Collection
from 1996-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1996
- MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Breast Neoplasms, Male * pathology mortality therapy drug therapy MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Czech Republic MeSH
PURPOSE: Male breast cancer (MBC) is a rare, but increasingly common disease, and lacks prospective studies. Collaborative efforts are needed to understand and address MBC, including its prognosis, in different countries. METHODS: We retrospectively reviewed the clinical, histopathological, and molecular-genetic characteristics, treatments, and survival outcomes of MBC diagnosed between 2007 and 2017 in the Czech Republic. Prognostic factors of overall survival (OS), recurrence-free interval (RFi), and breast cancer-specific mortality (BCSM) were analyzed and indirectly compared to international data. RESULTS: We analyzed 256 patients with MBC (median age 66 years), including 12% with de novo metastatic (M1). Of 201 non-metastatic (M0) patients, 6% were <40 years old, 29% had stage I, 55% were cN0, and 54% underwent genetic testing. Overall, 97% of tumors had estrogen receptor expression ≥10%, 61% had high Ki67 index, 40% were high-grade (G3), and 68% were luminal B-like (HER2-negative). Systemic therapies included endocrine therapy (90%) and chemotherapy (53%). Few (5%) patients discontinued adjuvant endocrine therapy for reasons other than disease relapse or death. Patients treated with aromatase inhibitors alone had significantly shorter RFi (P < .001). OS, RFi, and BCSM were associated with disease stage, T stage, N stage, progesterone receptor expression, grade, and Ki67 index. Median OS reached 122 and 42 months in M0 and de novo M1 patients, respectively. CONCLUSION: Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Comprehensive Oncology Center The Liberec Regional Hospital Liberec Czech Republic
Department of Clinical Oncology Na Homolce Hospital Prague Czech Republic
Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Brno Czech Republic
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Mathematics and Statistics Faculty of Science Masaryk University Brno Czech Republic
Department of Oncology AntiCa Kladno Czech Republic
Department of Oncology Hospital of Chomutov Chomutov Czech Republic
Faculty of Health Studies Pardubice University Pardubice Czech Republic
Institute of Radiation Oncology Faculty Hospital Bulovka Prague Czech Republic
Oncology Department T Baťa Regional Hospital Zlín Zlin Czech Republic
Research Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013588
- 003
- CZ-PrNML
- 005
- 20240905133806.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/oncolo/oyae031 $2 doi
- 035 __
- $a (PubMed)38431780
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bielcikova, Zuzana $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000184349848 $7 xx0225233
- 245 10
- $a Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic / $c Z. Bielcikova, M. Holanek, I. Selingerova, O. Sorejs, I. Kolarova, R. Soumarova, J. Proks, L. Reifova, V. Cmejlova, L. Linkova, M. Zabojnikova, M. Chodacka, L. Janovska, L. Lisnerova, K. Kasparova, D. Pohankova, L. Petruzelka
- 520 9_
- $a PURPOSE: Male breast cancer (MBC) is a rare, but increasingly common disease, and lacks prospective studies. Collaborative efforts are needed to understand and address MBC, including its prognosis, in different countries. METHODS: We retrospectively reviewed the clinical, histopathological, and molecular-genetic characteristics, treatments, and survival outcomes of MBC diagnosed between 2007 and 2017 in the Czech Republic. Prognostic factors of overall survival (OS), recurrence-free interval (RFi), and breast cancer-specific mortality (BCSM) were analyzed and indirectly compared to international data. RESULTS: We analyzed 256 patients with MBC (median age 66 years), including 12% with de novo metastatic (M1). Of 201 non-metastatic (M0) patients, 6% were <40 years old, 29% had stage I, 55% were cN0, and 54% underwent genetic testing. Overall, 97% of tumors had estrogen receptor expression ≥10%, 61% had high Ki67 index, 40% were high-grade (G3), and 68% were luminal B-like (HER2-negative). Systemic therapies included endocrine therapy (90%) and chemotherapy (53%). Few (5%) patients discontinued adjuvant endocrine therapy for reasons other than disease relapse or death. Patients treated with aromatase inhibitors alone had significantly shorter RFi (P < .001). OS, RFi, and BCSM were associated with disease stage, T stage, N stage, progesterone receptor expression, grade, and Ki67 index. Median OS reached 122 and 42 months in M0 and de novo M1 patients, respectively. CONCLUSION: Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory prsu u mužů $x patologie $x mortalita $x terapie $x farmakoterapie $7 D018567
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři nad 80 let $7 D000369
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Holanek, Milos $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Selingerova, Iveta $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Sorejs, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Kolarova, Iveta $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $u Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic
- 700 1_
- $a Soumarova, Renata $u Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Proks, Jan $u Clinic of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Reifova, Lucie $u Institute of Radiation Oncology, Faculty Hospital Bulovka, Prague, Czech Republic
- 700 1_
- $a Cmejlova, Vlastimila $u Department of Oncology, Second Medical Faculty, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Linkova, Lenka $u Comprehensive Oncology Center, The Liberec Regional Hospital, Liberec, Czech Republic
- 700 1_
- $a Zabojnikova, Michaela $u Oncology Department, T.Baťa Regional Hospital Zlín, Zlin, Czech Republic
- 700 1_
- $a Chodacka, Martina $u Department of Oncology, Hospital of Chomutov, Chomutov, Czech Republic
- 700 1_
- $a Janovska, Lucie $u Department of Oncology, First Faculty of Medicine of Charles University, General University Hospital in Prague and Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Lisnerova, Lenka $u Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Kasparova, Karolina $u Department of Oncology, AntiCa, Kladno, Czech Republic
- 700 1_
- $a Pohankova, Denisa $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Petruzelka, Lubos $u Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00005061 $t The oncologist $x 1549-490X $g Roč. 29, č. 6 (2024), s. e750-e762
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38431780 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133800 $b ABA008
- 999 __
- $a ok $b bmc $g 2143410 $s 1225454
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 29 $c 6 $d e750-e762 $e 20240603 $i 1549-490X $m The oncologist $n Oncologist $x MED00005061
- GRA __
- $a 00064165 $p Ministry of Health of the Czech Republic-conceptual development of research organization
- GRA __
- $a 00064165 $p Ministry of Health of the Czech Republic
- LZP __
- $a Pubmed-20240725
